Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic
Solid cancers are a leading cause of death worldwide, primarily due to the failure of effective clinical detection and treatment of metastatic disease in distant sites. There is growing evidence that the presence of circulating tumor cells (CTCs) in the blood of cancer patients may be an important i...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2010/426218 |
id |
doaj-721261ec0b8c427f8347ab19c2305817 |
---|---|
record_format |
Article |
spelling |
doaj-721261ec0b8c427f8347ab19c23058172020-11-24T22:40:26ZengHindawi LimitedJournal of Oncology1687-84501687-84692010-01-01201010.1155/2010/426218426218Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the ClinicAlison L. Allan0Michael Keeney1London Regional Cancer Program, London Health Sciences Centre, London, ON, N6A 5W9, CanadaLawson Health Research Institute, London, ON, N6A 4V2, CanadaSolid cancers are a leading cause of death worldwide, primarily due to the failure of effective clinical detection and treatment of metastatic disease in distant sites. There is growing evidence that the presence of circulating tumor cells (CTCs) in the blood of cancer patients may be an important indicator of the potential for metastatic disease and poor prognosis. Technological advances have now facilitated the enumeration and characterization of CTCs using methods such as PCR, flow cytometry, image-based immunologic approaches, immunomagnetic techniques, and microchip technology. However, the rare nature of these cells requires that very sensitive and robust detection/enumeration methods be developed and validated in order to implement CTC analysis for widespread use in the clinic. This review will focus on the important technical and statistical considerations that must be taken into account when designing and implementing CTC assays, as well as the subsequent interpretation of these results for the purposes of clinical decision making.http://dx.doi.org/10.1155/2010/426218 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alison L. Allan Michael Keeney |
spellingShingle |
Alison L. Allan Michael Keeney Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic Journal of Oncology |
author_facet |
Alison L. Allan Michael Keeney |
author_sort |
Alison L. Allan |
title |
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic |
title_short |
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic |
title_full |
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic |
title_fullStr |
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic |
title_full_unstemmed |
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic |
title_sort |
circulating tumor cell analysis: technical and statistical considerations for application to the clinic |
publisher |
Hindawi Limited |
series |
Journal of Oncology |
issn |
1687-8450 1687-8469 |
publishDate |
2010-01-01 |
description |
Solid cancers are a leading cause of death worldwide, primarily due to the failure of effective clinical detection and treatment of metastatic disease in distant sites. There is growing evidence that the presence of circulating tumor cells (CTCs) in the blood of cancer patients may be an important indicator of the potential for metastatic disease and poor prognosis. Technological advances have now facilitated the enumeration and characterization of CTCs using methods such as PCR, flow cytometry, image-based immunologic approaches, immunomagnetic techniques, and microchip technology. However, the rare nature of these cells requires that very sensitive and robust detection/enumeration methods be developed and validated in order to implement CTC analysis for widespread use in the clinic. This review will focus on the important technical and statistical considerations that must be taken into account when designing and implementing CTC assays, as well as the subsequent interpretation of these results for the purposes of clinical decision making. |
url |
http://dx.doi.org/10.1155/2010/426218 |
work_keys_str_mv |
AT alisonlallan circulatingtumorcellanalysistechnicalandstatisticalconsiderationsforapplicationtotheclinic AT michaelkeeney circulatingtumorcellanalysistechnicalandstatisticalconsiderationsforapplicationtotheclinic |
_version_ |
1725704950372106240 |